An ultrasonography-based contrast-enhanced for distinguishing between benign and malignant hepatocellular carcinoma

Abstract

To analyze the practical value of contrast-enhanced ultrasound in liver benign and malignant tumors. 60 patients with liver tumors were chosen as research materials from June 2019 to October 2021, and their malignant and benign tumors were analyzed by contrast-enhanced ultrasound. Results show ultrasonic imaging was used to test the sensitivity of liver malignant tumor, coincidence rate 92.7% to 92.9%, and index of 78 were significantly higher than that of conventional ultrasound (χ2 = 8.8000, 9.9068, 9.3544, p<0.01). The initial increase time (18.25±3.04), peak time (35.73±8.43), decreased time (55.42±0.89), and continuous enhancement time (84.96±1.57) for benign liver tumors were all higher than those for malignant tumors (t = 5.3487, 5.4924, 37.0273, 82.0934, p <0.01). The peak intensity of contrast enhanced ultrasound for benign tumors (19.57±3.43) was lower than that for malignant tumors (t = 4.3096, p<0.01). So, contrast-enhanced ultrasound has significant value in differentiating benign from malignant liver tumors.